Sandra Pennell
Known title: SVP of Finance, PFO and PAOCIK: 0001824817
Sandra Pennell's purchase track record
Sandra Pennell has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/6/2026 | DCTH | $50K | +17.5% | +81.5% | +14.5% |
| 11/17/2023 | DCTH | $73K | +79.6% | +209.0% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DCTH | ▲ Buy | Open Market | 5,533 | $50K | 3/6/2026 | View on chart |
| DCTH | ▲ Buy | Grant | 26,881 | $100K | 3/19/2024 | View on chart |
| DCTH | ▲ Buy | Open Market | 30,000 | $73K | 11/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Veracyte stock moves; DCTH shows no related news
Recent news coverage focuses on Veracyte (VCYT) rather than Delcath Systems (DCTH). There are no specific reports or announcements regarding DCTH in the provided data. The stock currently trades with a high trailing P/E ratio, while analyst targets remain above the current price level.
Veracyte stock moves; DCTH shows no related news. Recent news coverage focuses on Veracyte (VCYT) rather than Delcath Systems (DCTH). There are no specific reports or announcements regarding DCTH in the provided data. The stock currently trades with a high trailing P/E ratio, while analyst targets remain above the current price level.